Spinogenix Taps Harvard Neuroscience Chair for Scientific Advisory Board
Event summary
- Spinogenix appointed Professor Joseph T. Coyle, MD, Chair of Psychiatry and Neuroscience at Harvard Medical School, to its Scientific Advisory Board on July 2, 2026.
- Prof. Coyle will provide strategic guidance for Spinogenix's neuroscience pipeline, with a focus on schizophrenia.
- Spinogenix is advancing tazbentetol (formerly SPG302) across multiple neurodegenerative and neuropsychiatric indications.
- Tazbentetol has received Orphan Drug designations from FDA and EMA for ALS, and Fast Track designation for SPG601 in Fragile X Syndrome.
The big picture
Spinogenix's appointment of a leading Harvard neuroscience expert underscores its strategic focus on advancing synaptic regenerative therapies. The move comes as the company seeks to differentiate itself in a competitive neuroscience landscape, where breakthroughs in schizophrenia and other neuropsychiatric disorders are highly sought after. Prof. Coyle's deep expertise in EEG biomarkers and translational research could be pivotal in validating Spinogenix's novel approach.
What we're watching
- Clinical Development Pace
- How Prof. Coyle's expertise will accelerate the clinical development of tazbentetol, particularly in schizophrenia.
- Regulatory Strategy
- Whether Spinogenix can leverage Fast Track and Orphan Drug designations to expedite approvals for its pipeline.
- Scientific Validation
- The impact of Prof. Coyle's involvement on the scientific credibility and investor confidence in Spinogenix's approach.